• 제목/요약/키워드: drug-therapy

검색결과 1,321건 처리시간 0.023초

소화기 암환자 호흡곤란의 정확한 평가와 치료 (Accurate Evaluation and Treatment of Dyspnea in Patients with Gastrointestinal Cancer)

  • 이종윤
    • Journal of Digestive Cancer Research
    • /
    • 제11권2호
    • /
    • pp.108-113
    • /
    • 2023
  • Dyspnea is a common symptom among patients with gastrointestinal cancer, and a comprehensive evaluation of their respiratory function is essential. Self-reporting aids in the assessment of the degree of dyspnea, while objective examination methods are performed to identify the potential underlying causes when subjective symptoms are present. Standard treatment protocols should be followed for potentially reversible and common causes of dyspnea, such as pleural effusion, pneumonia, airway obstruction, anemia, asthma, exacerbation of chronic obstructive pulmonary disease, pulmonary thromboembolism, or drug-induced interstitial lung disease. Careful and close monitoring is required due to the high frequency of pulmonary thromboembolism and the risk of cardiovascular accidents, drug-induced interstitial lung disease, or other complications from some anticancer drugs. In case of hypoxemia with an oxygen saturation of 90% or less, palliative treatment should comprise standard oxygen therapy such as nasal cannula, mask, or high-flow nasal cannula. If non-pharmacological oxygen therapy is not effective, pain control through systemic narcotic analgesics and anti-anxiety therapy with benzodiazepines may be helpful.

부산지역의 한 3차 진료기관을 방문한 폐결핵 환자의 약제내성률 (Drug-Resistant Pulmonary Tuberculosis In Kosin Medical Center)

  • 김지호;김지홍;장태원;정만홍
    • Tuberculosis and Respiratory Diseases
    • /
    • 제42권6호
    • /
    • pp.831-837
    • /
    • 1995
  • 연구목적: 폐결핵 치료에서 약재내성은 큰 문제가 된다. 특히 다제 약제 내성은 환자 자신 뿐만 아니라 예방의학적 측면에서도 큰 문제가 되고 있다. 3차 의료기관에 오는 폐결핵 환자들에서 약제 내성의 발현 정도, 양상 및 관계되는 요인 등을 조사하여 내원 환자들의 향후 치료에 도움이 되는 지표를 알아 보고자 하였다. 대상 및 방법: 1986년 부터 1994년 사이 고신의료원 내과를 방문하여 폐결핵으로 진단되어 약제내성 검사를 한 141명의 환자를 대상으로 약제 내성률과 과거 치료 병력, 흉부 X-선 사진상 폐의 침범 정도와 공동의 유무 등의 관계를 후향적으로 조사하였다. 성적: 141 명중 59명(41.8%)에서 한 가지 약제 이상에 내성야 있었고 INH와 RIF에 동시 내성이 있는 경우는 139명중 29명(20.9%)였다. 과거에 결핵 치료를 63명중 40명(63.5%)에서 약제 내성이 있었고 24명(38.1%)에서 다제 약제 내성이 있었다. 과거 결핵치료 병력이 없는 78명중 19명(24.4%)에서 약제내성이 있었고 5명(6.5%)에서는 다제 약제 내성이 있었다. 약제별로는 INH내성이 39.0%로 가장 높았고 RIF(21.6%), EMB(16.3%), PAS(10.8%), SM(8.7%), PZA(8.0%) 순이었다. INH, RIF 및 PZA에 대한 내성은 과거 치료 병력이 있는 경우에서 높았고(odds ratio 각각 3.3, 7.2 및 10.8), 흉부 X-선 사진상 침범부위가 RIF 및 SM에 대한 내성률이 유의하게 높았다(odds ratio 각각 2.9, 2.8). 결론: 높은 약제 내성률로 보아 약제 감수성검사는 모든 환자들에게 시행해야 하겠으며, 그 결과가 나오기 전까지는 4가지 이상의 약제를 사용하는 것이 안전할 것으로 생각된다. 그리고 특히 과거에 치료한 병력이 있거나 진행된 폐결핵 환자의 경우는 철저한 임상적 및 세균학적인 추적관찰이 필요할 것으로 생각한다.

  • PDF

Geometry effect in the drug delivery for therapy with nanomedicines based on the conditions of the sport

  • Zhu, Lemei;Zou, Xuemin;Li, Xi;Zhang, Yuan;Liu, Juan;Xiang, Yuhan
    • Advances in nano research
    • /
    • 제13권3호
    • /
    • pp.217-231
    • /
    • 2022
  • This study investigates the geometrical impact on the nanomedicine drug delivery via nanodevices. A nanomotor made of the nanotube carrying the drug as the motor blade is considered in the blood flow. Physical activities change the blood flow, and sports training enhances the blood flow and plays a significant role in the stability of drug delivery devices. This paper studies the impact of geometrical parameters on the nanomotors carrying the nanomedicine. The effect of physical exercise on the dynamic response regarding the stability of drug delivery devices is discussed in detail.

임신 중에 흡연이 미치는 영향 (Effects of Smoking During Pregnancy)

  • 노효련
    • 대한물리치료과학회지
    • /
    • 제9권3호
    • /
    • pp.151-159
    • /
    • 2002
  • The purpose of this study were to discribe the influence of maternal smoking during pregnancy from referance. The offspring of mothers who smoked during pregnancy had more than risk of having committed crimes, deformities, premature, drug abuse, psychiatry et al. This study suggested that prohibition of smoking for women.

  • PDF

관동맥질환 치료의 최신 지견 (Updates in the Management of Coronary Artery Disease)

  • 양동헌;채성철
    • 대한핵의학회지
    • /
    • 제39권2호
    • /
    • pp.87-93
    • /
    • 2005
  • Coronary artery disease (CAD) has been increasing during the last decade and is the one of major causes of death. The management of patients with coronary artery disease has evolved considerably. There are two main strategies in the management of CAD, complementary, not competitive, each other; the pharmacologic therapy to prevent and treat CAD and the percutaneous coronary Intervention (PCI) to restore coronary flow. Antiplatelet drugs and cholesterol lowering drugs have central roles in pharmacotherapy. Drug eluting stent (DES) bring about revolutional changes in PCI. In the management of patients with 57 segment elevation acute myocardial infarction (AMI), there has been a debate on the better strategy for the restoration of coronary flow. Thrombolytic therapy is widely available and easy to administer, whereas primary PCI is less available and more complex, but mote complete. Recently published evidences in the pharmacologic therapy including antiplatelet and stalin, and PCI including DES and reperfusion therapy in patients with ST segment elevation AMI were reviewed.

The Effects of Nafamostat Mesilate on a Bleeding Risk as an Anticoagulant During Use as a Continuous Renal Replacement Therapy: Systematic Review

  • Kang, YoungJu;Moon, Su Jee;Kang, Hye-Young
    • 보건의료기술평가
    • /
    • 제6권2호
    • /
    • pp.133-141
    • /
    • 2018
  • Objectives: In the past, the pharmaceutical drug heparin was mostly used as the anticoagulant for continuous renal replacement therapy (CRRT), but the duration time is long to have the risk of a bleeding adverse effect, and in that case the drug therapy Nafamostat mesilate was utilized instead, as it is more safe in this case, with a short half-life and is increasing in use to permit lower concerns for bleeding incidents. However, there are insufficient number of large-scale studies on the comparison of Nafamostat mesilate and heparin. Methods: In this study, a systematic review are used to compare the bleeding risk of Nafamostat mesilate and Heparin, as subjected to patients and procedures for measuring risks performed with a CRRT, and the filter life span is to be evaluated as well in this patients. Results: As a result of literature review search, a total of 6 studies were included in systematic review. The reducing risk of bleeding and filter life span was analyzed. The retrospective cohort studies confirm that Nafamostat mesilate is less at risk of bleeding than heparin. And a cohort study confirms that Nafamostat mesilate is longer filter lifespan than heparin and randomized controlled trial studies show that Nafamostat mesilate is longer filter lifespan than not using the anticoagulants. Conclusion: Nafamostat mesilate is considered to be a good therapeutic option because it has a longer filter life span as well as the advantage of reducing bleeding.